Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)

NCT04150965 is registered in ClinicalTrials.gov with Multiple Myeloma Research Consortium as lead sponsor.

NCT NCT04150965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)
Lead sponsor
Multiple Myeloma Research Consortium
Phase
Phase 1/2
Overall status
Terminated
Start date
July 10, 2020
Completion date
August 30, 2024
Enrollment
14 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, relapsed refractory multiple myeloma